Literature DB >> 26337137

Tetrazolylhydrazides as Selective Fragment-Like Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.

Nicole Rüger1, Martin Roatsch2, Thomas Emmrich1, Henriette Franz3, Roland Schüle3, Manfred Jung2, Andreas Link4.   

Abstract

The JumonjiC-domain-containing histone demethylase 2A (JMJD2A, KDM4A) is a key player in the epigenetic regulation of gene expression. Previous publications have shown that both elevated and lowered enzyme levels are associated with certain types of cancer, and therefore the definite role of KDM4A in oncogenesis remains elusive. To identify a novel molecular starting point with favorable physicochemical properties for the investigation of the physiological role of KDM4A, we screened a number of molecules bearing an iron-chelating moiety by using two independent assays. In this way, we were able to identify 2-(1H-tetrazol-5-yl)acetohydrazide as a novel fragment-like lead structure with low relative molecular mass (Mr =142 Da), low complexity, and an IC50 value of 46.6 μm in a formaldehyde dehydrogenase (FDH)-coupled assay and 2.4 μm in an antibody-based assay. Despite its small size, relative selectivity against two other demethylases could be demonstrated for this compound. This is the first example of a tetrazole group as a warhead in JMJD demethylases.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  acyl hydrazides; acyl hydrazones; epigenetics; histone demethylase; tetrazoles

Mesh:

Substances:

Year:  2015        PMID: 26337137     DOI: 10.1002/cmdc.201500335

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  8 in total

Review 1.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

2.  Substituted tetrazoles as multipurpose screening compounds.

Authors:  Nicole Rüger; Georg Michael Fassauer; Christian Bock; Thomas Emmrich; Anja Bodtke; Andreas Link
Journal:  Mol Divers       Date:  2016-12-27       Impact factor: 2.943

Review 3.  Recent Advances with KDM4 Inhibitors and Potential Applications.

Authors:  Qiong Wu; Brandon Young; Yan Wang; Andrew M Davidoff; Zoran Rankovic; Jun Yang
Journal:  J Med Chem       Date:  2022-07-15       Impact factor: 8.039

4.  Design, synthesis, and evaluation of novel racecadotril-tetrazole-amino acid derivatives as new potent analgesic agents.

Authors:  Mehdi Asadi; Maryam Mohammadi-Khanaposhtani; Faezeh Sadat Hosseini; Mahdi Gholami; Ahmad Reza Dehpour; Massoud Amanlou
Journal:  Res Pharm Sci       Date:  2021-06-30

5.  Upregulation of PSMD10 caused by the JMJD2A histone demethylase.

Authors:  Tae-Dong Kim; Sangphil Oh; Stan A Lightfoot; Sook Shin; Jonathan D Wren; Ralf Janknecht
Journal:  Int J Clin Exp Med       Date:  2016-06-30

Review 6.  Iron in the Tumor Microenvironment-Connecting the Dots.

Authors:  Christa Pfeifhofer-Obermair; Piotr Tymoszuk; Verena Petzer; Günter Weiss; Manfred Nairz
Journal:  Front Oncol       Date:  2018-11-26       Impact factor: 6.244

7.  Structure-Based Screening of Tetrazolylhydrazide Inhibitors versus KDM4 Histone Demethylases.

Authors:  Piotr H Małecki; Nicole Rüger; Martin Roatsch; Oxana Krylova; Andreas Link; Manfred Jung; Udo Heinemann; Manfred S Weiss
Journal:  ChemMedChem       Date:  2019-10-10       Impact factor: 3.466

Review 8.  The emerging role of KDM5A in human cancer.

Authors:  Guan-Jun Yang; Ming-Hui Zhu; Xin-Jiang Lu; Yan-Jun Liu; Jian-Fei Lu; Chung-Hang Leung; Dik-Lung Ma; Jiong Chen
Journal:  J Hematol Oncol       Date:  2021-02-17       Impact factor: 17.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.